Niagen Bioscience Files 8-K
Ticker: NAGE · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1386570
| Field | Detail |
|---|---|
| Company | Niagen Bioscience, Inc. (NAGE) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, company-information
Related Tickers: CDXC
TL;DR
Niagen Bioscience (fka ChromaDex) filed an 8-K on Oct 6, 2025.
AI Summary
Niagen Bioscience, Inc. filed an 8-K on October 6, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as ChromaDex Corp., is incorporated in Delaware and headquartered in Los Angeles, California.
Why It Matters
This filing provides regulatory updates and financial information for Niagen Bioscience, Inc., formerly ChromaDex Corp., which is relevant for investors and stakeholders tracking the company's compliance and financial status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and does not indicate any immediate material events.
Key Numbers
- 001-37752 — SEC File Number (Identifies the company's filing with the SEC)
- 26-2940963 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Niagen Bioscience, Inc. (company) — Registrant
- ChromaDex Corp. (company) — Former company name
- October 6, 2025 (date) — Date of report
- Los Angeles, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Niagen Bioscience, Inc.?
The 8-K filing serves to report information under Regulation FD Disclosure and Financial Statements and Exhibits, as of October 6, 2025.
What was Niagen Bioscience, Inc. previously known as?
Niagen Bioscience, Inc. was formerly known as ChromaDex Corp.
In which state is Niagen Bioscience, Inc. incorporated?
Niagen Bioscience, Inc. is incorporated in Delaware.
What is the address of Niagen Bioscience, Inc.'s principal executive offices?
The principal executive offices are located at 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024.
What is the SEC file number for Niagen Bioscience, Inc.?
The SEC file number for Niagen Bioscience, Inc. is 001-37752.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-06 16:04:56
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NAGE The Nasdaq Capital Mar
Filing Documents
- cdxc-20251006.htm (8-K) — 24KB
- pressreleasedatedoctober62.htm (EX-99.1) — 18KB
- 0001386570-25-000015.txt ( ) — 158KB
- cdxc-20251006.xsd (EX-101.SCH) — 2KB
- cdxc-20251006_lab.xml (EX-101.LAB) — 21KB
- cdxc-20251006_pre.xml (EX-101.PRE) — 12KB
- cdxc-20251006_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 6, 2025, Niagen Bioscience, Inc. (the "Company") issued a press release announcing that it has increased its financial outlook for the full year ending December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NIAGEN BIOSCIENCE, INC. Dated: October 6, 2025 By: /s/ Ozan Pamir Name: Ozan Pamir Chief Financial Officer (principal financial officer and duly authorized on behalf of the registrant)